Business is the art of sharing, which is why at Balanced Biotech we want to share knowledge, experience and profits. We are able to adapt our business model to the preferences and needs of our Business Partners. We are open to any building arrangements to work out a win-win model.
We are a talented group of entrepreneurs, scientists and engineers with groundbreaking ideas and technologies that will contribute towards a better tomorrow. We provide smart solutions for patients and their families and pride ourselves on our unparalleled dedication and passion for success.
At Balanced Biotech, Inc. our vision is to transform how the world approaches the treatment of acute and life-threatening disease by utilizing one of the most efficient transdermal drug delivery applications developed to date.
Our Patented proprietary carriers of active substances can also be used as a transport system for commonly used oncological, anti-inflammatory, analgesic drugs and many more, increasing their targeted effects by up to 10 times, reducing the drug dose by 10 times and radically minimizing the side effects of therapy.
Our mission is to improve the patients’ experience and quality of life through innovative drug transport systems that will revolutionize the pharmaceutical market. The first technologies and formulas by the Balanced team have been developed to help high risk patients.
Balanced Biotech's formulas with a cutting-edge delivery technology makes it possible to achieve remarkable results compared to traditional drugs. We started Balanced Biotech to solve complex technological problems and develop unique systems to produce better outcomes while helping people around the world.
According to the MARKETSANDMARKETS report “Transdermal Second Delivery System Market – Global Forecast to 2022”, the global market for transdermal drug delivery systems (TDDS) in 2017 amounted to nearly $35.72 billion. By 2024, the TDDS market will be worth $81.46 billion. The average market growth is estimated at a record level of 12.5% per year.
Balanced Biotech's Pipeline
(Multifunctional Transdermal Carrier)
Is a game changing transdermal carrier of active substances, increasing their bioavailability. The mixture of auxiliary substances constituting the MTC-Y carrier consists of elements ensuring the introduction into the body of several active substances of different natural and active pharmaceutical ingredient properties in parallel. In addition, each of them can be introduced simultaneously in different polymorphs, which enables the creation of preparations with a modified action profile. License from Biotts Biotech SA for use with U1 & U1/NA.
According to a WHO report, 8.8 million people worldwide died of cancer in 2015, representing about 1 in 6 of all deaths. In 2015, 774,000 people died of bowel cancer, of which rectal cancer accounted for 25%. According to Grand View Research, the value of medicines sold for intestinal cancer will be $8.9 billion in 2018, reaching $10.8 billion in 2022 and $12 billion in 2025.
MTC-U1 & U1/NA Oncology
The MTC-U1 &U1/NA mixture supporting the treatment of breast cancer was created based on the MTC-Y transdermal therapeutic system enriched with natural absorption promoters and extracts of active substances. Thanks to the simultaneous use of a deeply penetrating transdermal system and specific, selective absorption promoters, it is possible to transport active substances that inhibit the proliferation of diseased tissues. As a result of the technological solutions used, a product softening solid tumor tissues was created, while sensitizing them to the effects of anti-cancer substances.
1 in 8 women in the world is diagnosed with breast cancer and every 29 seconds a new case of breast cancer is confirmed.
In 2012, 1,700,000 women worldwide developed breast cancer. In the same year, 500,000 women died of breast cancer.
Breast cancer is the most common type of cancer, accounting for as much as 21% of detected cases.
In 2018, the global market for breast cancer medicines was worth $13.4 billion, and in 2021 it will reach $17.2 billion. According to the GlobeNewswire report, the market for oncological drugs for breast cancer by 2025 may even grow to the level of $28 billion.
Advancing With Technology
Technology makes the difference, better drug delivery systems and technological advances are at the core of all that we do at Balanced Biotech. Thanks to the unique properties of a cutting-edge delivery system, it is possible to increase the bioavailability of active substances up to 10 times and enable active substances to penetrate through skin barriers up to several centimeters. Thanks to this unique formula, it is possible to reduce the doses of substances and at the same time to intensify their action. The effect is the acceleration of treatment with reduced side effects.
Cancer drugs can cause enormous toxicity; therefore, the opportunity to deliver them locally creates the possibility of improving both the safety and efficacy of cancer chemotherapy.
Our MTC-Y Technology is a game changing MultiFunctional Transdermal Carrier delivering antineoplastic agents & several other molecules to a specific site which reduces side effects, increases patient compliance and offers better outcomes.
We investigated the anticancer activity of our proprietary multifunctional transdermal carrier with two active substances: MTC-U1 and its modification MTC-U1-NA; developed in partnership by Balanced Biotech and BIOTTS S.A., on MCF and LoVo cancer cell lines in in vivo conditions.
Both preparations showed high efficacy in destroying implanted neoplastic cells of the LoVo and MCF lines, without any damage within other organs.
Extensive necrotic areas of tumor cells, mainly in the subcutaneous tissue, were observed in the group. The preparation displayed a very high efficacy in inhibiting the development of neoplastic cells.
The transdermal penetration of drugs using different formulations such as nanocarriers, physical penetration enhancement techniques, chemical penetration enhancers and newer technologies show improved patient compliance, reduce side effects, create economic value and provide a better pharmacokinetic profile.